Business Wire

Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology

Share

Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced that OptiLight has received the highly competitive MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” This year, MedTech’s range of health and medical technology categories attracted more than 3,900 nominations from over 15 countries, from which MedTech selected OptiLight for this prestigious recognition. The win follows Lumenis’ MedTech awards for Best Overall Medical Device Company in 2021 and Best New Surgical Technology Solution in 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005607/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

OptiLight is a groundbreaking, light-based treatment. It is the first and only light treatment FDA approved for management of dry eye disease, a very common condition that causes dry, gritty eyes and fluctuating vision for an estimated 49 million Americans.1 Lumenis’ patented, innovative Optimal Pulse Technology (OPT™) offers targeted, uniform, precise, and controlled treatment that safely and effectively breaks the vicious cycle of inflammation associated with dry eye disease.

“Dry eye disease is highly prevalent and difficult to manage, and traditional treatments like warm compresses and artificial tears treat the symptoms but not the underlying pathology,” said James Johnson, managing director, MedTech Breakthrough. “OptiLight is leading a revolution in managing dry eye disease with ‘breakthrough’ technology that allows doctors to treat patients quickly, in-office. With broad potential for tens of millions with dry eye disease, OptiLight stands out from the crowd to become our 2022 Best New Technology Solution for Ophthalmology.”

Lumenis introduced OptiLight in May 2021 and recently launched a national media campaign featuring singer-songwriter and actress Mandy Moore (This Is Us) to increase awareness for dry eye disease and encourage people who might be suffering from this condition to seek out a physician who offers OptiLight (www.TreatMyDryEye.com).

“We’re grateful to MedTech for honoring OptiLight for its innovation and impact in eye care,” said Lumenis CEO Tzipi Ozer-Armon. “Lumenis is committed to raising the bar for patients’ health by providing cutting-edge solutions and treatment innovations. As the only light-based treatment for dry eye disease, OptiLight has the power to elevate dry eye management and improve health and quality of life for millions of people around the world.”

1. Dana R et al. Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. Am J Ophthalmol. 2020 Aug; 216:7-17.

About Lumenis

www.lumenis.com

Lumenis is a leading energy-based medical device company for aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. It is regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ groundbreaking products have redefined medical treatments and have set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.

About MedTech Breakthrough

Part ofTech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

PB-00044810 Rev A

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Colleen Ketchum
colleen.ketchum@precisionvh.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PUMA Football Players and Athletes Nikita Parris, Ingrid Engen, Fridolina Rolfö and Sara Björk Gunnarsdottir Talk “She Moves Us” Ahead of Women’s Euro in England27.6.2022 19:40:00 CEST | Press release

Football players and PUMA Athletes spoke frankly about the sacrifices and challenges of being a female professional football player in a “She Moves Us” video conversation for Sports company PUMA: “I’ve had to challenge male standards just by being a football player. I think most people in the world see it as a male sport, but for me it’s the same. We do the same. Everything around should be the same as well. So that’s what we’re fighting for and trying to show the world”, says Norwegian National Team Player Ingrid Engen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005655/en/ PUMA football players and athletes Nikita Parris, Ingrid Engen, Fridolina Rolfö and Sara Björk Gunnarsdottir talk “She Moves Us” ahead of Women’s Euro in England (Photo: Business Wire) English Football Star Nikita Parris was amazed by the changes that are happening with the respect for female professional athletes:” I had to challenge male stand

Kalray’s Smart Storage Acceleration Card K200-LP™, Now Integrated into Pixitmedia’s Software-Defined Storage Solution Pixstor27.6.2022 18:00:00 CEST | Press release

Kalray (Euronext Growth Paris : ALKAL) (Paris:ALKAL),a leading provider in the new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, is delighted to announce the first outcome of the synergetic combination of its DPU (“Data Processing Unit”) processor-based acceleration card K200-LP™ with newly acquired software-defined storage and data management solutions provider pixitmedia1, a division of Arcapix Holdings Ltd dedicated to the Media & Entertainment markets. The launch of this new joint product comes just months after Kalray's acquisition of Arcapix Holdings Ltd and the new product will be showcased at Flash Memory Summit (USA) in August. KALRAY’S ACCELERATION CARDS AND DPUs AT THE HEART OF AWARDED PIXITMEDIA’S SOFTWARE-DEFINED STORAGE AND DATA MANAGEMENT SOLUTIONS Media & Entertainment customers are amongst the most demanding in terms of data storage and data management. The award winning pixstor and ngenea products are de

CORRECTING and REPLACING Minister of Trade and Industry to Launch the Norwegian Government’s Battery Strategy at FREYR Battery’s Mo i Rana Site27.6.2022 17:59:00 CEST | Press release

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005371/en/ "Sentraltomta" inside Mo Industrial Park (Photo: Business Wire) The updated release reads: MINISTER OF TRADE AND INDUSTRY TO LAUNCH THE NORWEGIAN GOVERNMENT’S BATTERY STRATEGY AT FREYR BATTERY’S MO I RANA SITE FREYR Battery (NYSE: FREY) (“FREYR”), a developer of clean, next-generation battery cell production, is pleased to confirm that the company will welcome the Minister of Trade and Industry to launch the Norwegian Government’s National Battery Strategy at FREYR’s planned gigafactory location on June 29th in Mo i Rana, Norway. FREYR’s Chief Executive Officer, Tom Einar Jensen, remarked, “We are exceptionally proud that the Norwegian Government has selected FREYR’s planned gigafactory site in Mo i Rana to make this historic announcement. We look forward to extending a wa

Walton Global Makes Distributions of $137 Million to its Investors during Second Quarter 202227.6.2022 17:45:00 CEST | Press release

Walton Global, a real estate investment and land asset management company with US $3.6 billion under management, announced distributions made to investors will total more than US $137 Million in the second quarter 2022 as a result of strong land sales in various assets across North America. A total of US $130 Million has already been distributed to investors with more than US $7 Million expected to be made at the end of June 2022. “We have been managing our land sales pipeline diligently across all of our assets in both the U.S. and Canada,” said Kate Kaminski, chief operating officer at Walton Global. “This is the first large wave of investor distributions in 2022, but we have many other significant projects that are expected to close throughout the year.” Walton has investors that span across 73 countries around the globe. The US $137 Million distribution is an aggregate amount made up of U.S. and Canadian assets within Walton’s investment structures. U.S.-based investors received di

Landmark Study Reveals New Technology from DeBogy Molecular Significantly Reduces the Bacteria and Deadly Infection that Can Occur Following a Surgical Implant27.6.2022 15:15:00 CEST | Press release

DeBogy Molecular, Inc, a biotech startup that specializes in antimicrobial surface modification, today announced the findings of a landmark in vivo research study that affirms the effectiveness and safety of their new technology to kill the dangerous bacteria that proliferates on the surface of a medical implant following surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005067/en/ Wayne Gattinella CEO, DeBogy Molecular, Inc (Photo: Business Wire) Infection resulting from bacterial biofilm that forms on the surface of a medical implant represents one of the most serious complications that can follow orthopedic surgery or the implantation of a medical device. Implant related infections account for over half of the 2 million yearly healthcare-associated infections in the U.S., at a cost of over $27 billion dollars annually. A preclinical research study was conducted by Vivexia, an independent Clinical Research Orga

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom